Transgenic plant-derived pharmaceuticals - the practical approach?
Production of biopharmaceuticals in transgenic plants would involve the creation of a new industry. Those transgenic plants, including staple food crops, could provide many benefits to people all over the world. However, the new industry might require a strict regulation system. It is probable that such a strict system would not be acceptable to Japan or to most developing countries. Many countries should use non-food crops for production of biopharmaceuticals and take on more simple systems. The new industry must develop strategies for promoting the benefits of transgenic plant-derived biopharmaceuticals on both the domestic and worldwide scales.
Akira
A
Yano
Masataka
M
Takekoshi
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis / Q000302:isolation & purification; D004274:DNA, Recombinant / Q000235:genetics; D004340:Drug Contamination / Q000517:prevention & control; D015195:Drug Design; D005818:Genetic Engineering; D006801:Humans; D004364:Pharmaceutical Preparations / Q000302:isolation & purification*; D030821:Plants, Genetically Modified / Q000737:chemistry; D011499:Protein Processing, Post-Translational; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000302:isolation & purification; D012449:Safety; D013678:Technology, Pharmaceutical / Q000379:methods*
D000911:Antibodies, Monoclonal; D004274:DNA, Recombinant; D004364:Pharmaceutical Preparations; D011993:Recombinant Fusion Proteins